The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | The evolving tole of preservation in oesophageal adenocarcinoma and SCC
Sanjiv Gangaram-Panday, PhD, Erasmus University, Rotterdam, Netherlands, comments on the results of a subgroup analysis in the SANO trial (NTR-6803), noting that while there was no significant difference found for adenocarcinoma and squamous cell carcinoma, the results appear more favorable for squamous cell carcinoma (SCC) in terms of disease-free survival and distant dissemination rate. Organ preservation after neoadjuvant chemoradiotherapy remains a viable option for both adenocarcinoma and squamous cell carcinoma based on the current results. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We did do subgroup analysis and although already not powered in a secondary analysis, we do not find a difference for the adenocarcinoma and for the squamous cell carcinoma. We do see that the results are more favorable for squamous cell carcinoma, particularly if we look at disease-free survival and distant dissemination rate differences. But both for adenocarcinoma and squamous cell carcinoma, this remains a viable option based on all the results that we have so far
We did do subgroup analysis and although already not powered in a secondary analysis, we do not find a difference for the adenocarcinoma and for the squamous cell carcinoma. We do see that the results are more favorable for squamous cell carcinoma, particularly if we look at disease-free survival and distant dissemination rate differences. But both for adenocarcinoma and squamous cell carcinoma, this remains a viable option based on all the results that we have so far
Read more...
